CURE is usually one of the least volatile equity leveraged ETFs in Direxion’s lineup, but traders should still treat it as they would any other leveraged ETF.

“Leveraged and inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day,” according to Direxion.

Traders have added $7.26 million to CURE since the start of 2019.

For more on leveraged & inverse ETFs, please visit our Leveraged & Inverse Channel.